NO20042100D0 - Fremgangsmate for administrering av et tymosinalfa 1-peptid - Google Patents

Fremgangsmate for administrering av et tymosinalfa 1-peptid

Info

Publication number
NO20042100D0
NO20042100D0 NO20042100A NO20042100A NO20042100D0 NO 20042100 D0 NO20042100 D0 NO 20042100D0 NO 20042100 A NO20042100 A NO 20042100A NO 20042100 A NO20042100 A NO 20042100A NO 20042100 D0 NO20042100 D0 NO 20042100D0
Authority
NO
Norway
Prior art keywords
peptide
alpha
thymosinal
administering
patient
Prior art date
Application number
NO20042100A
Other languages
English (en)
Other versions
NO327101B1 (no
NO20042100L (no
Inventor
Alfred R Rudolph
Cynthia W Tuthill
Original Assignee
Sciclone Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciclone Pharmaceuticals Inc filed Critical Sciclone Pharmaceuticals Inc
Publication of NO20042100D0 publication Critical patent/NO20042100D0/no
Publication of NO20042100L publication Critical patent/NO20042100L/no
Publication of NO327101B1 publication Critical patent/NO327101B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
NO20042100A 2001-11-01 2004-05-21 Anvendelse av tymosinalfa 1 peptid NO327101B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33087401P 2001-11-01 2001-11-01
PCT/US2002/035093 WO2003037366A1 (en) 2001-11-01 2002-11-01 Method of administering a thymosin alpha 1 peptide

Publications (3)

Publication Number Publication Date
NO20042100D0 true NO20042100D0 (no) 2004-05-21
NO20042100L NO20042100L (no) 2004-05-21
NO327101B1 NO327101B1 (no) 2009-04-20

Family

ID=23291672

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20042100A NO327101B1 (no) 2001-11-01 2004-05-21 Anvendelse av tymosinalfa 1 peptid

Country Status (19)

Country Link
US (2) US20050049191A1 (no)
EP (1) EP1450850B1 (no)
JP (1) JP2005511563A (no)
KR (1) KR20050042229A (no)
CN (1) CN1582163A (no)
AT (1) ATE481980T1 (no)
AU (1) AU2002363248B2 (no)
BR (1) BR0213823A (no)
CA (1) CA2464307A1 (no)
DE (1) DE60237784D1 (no)
EA (1) EA008536B1 (no)
ES (1) ES2353379T3 (no)
IL (2) IL161665A0 (no)
MX (1) MXPA04004187A (no)
NO (1) NO327101B1 (no)
NZ (1) NZ532763A (no)
PL (1) PL208388B1 (no)
UA (1) UA80957C2 (no)
WO (1) WO2003037366A1 (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL377376A1 (pl) * 2002-11-25 2006-02-06 Sciclone Pharmaceuticals, Inc. Sposoby ochrony przed uszkodzeniem przez promieniowanie z użyciem Ó-tymozyny
ATE467422T1 (de) * 2003-03-28 2010-05-15 Sciclone Pharmaceuticals Inc Behandlung von aspergillus-infektionen mit thymosin alpha 1
US8017129B2 (en) 2006-06-15 2011-09-13 SciClone Pharmaceuticals International Ltd Use of thymosin alpha 1 for preparing a medicament for the treatment of stage IV malignant melanoma
US20080300166A1 (en) * 2007-06-01 2008-12-04 Sciclone Pharmaceuticals, Inc. Treatment of Melanoma with Alpha Thymosin Peptides
US20100317583A1 (en) * 2007-12-14 2010-12-16 Sciclone Pharmaceuticals, Inc. Treatment of melanoma with alpha thymosin peptides in combination with an antineoplastic heat shock apoptosis activator (hsaa)
WO2010129947A2 (en) 2009-05-08 2010-11-11 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers
EP2838551A4 (en) * 2012-03-08 2016-02-24 Sciclone Pharmaceuticals Inc USE OF THYMOSIN ALPHA FOR THE TREATMENT OF PURULENT RHINO-SINUSITIS
US20130296223A1 (en) 2012-03-30 2013-11-07 Sciclone Pharmaceuticals, Inc. Use of thymosin alpha for the treatment of sepsis
EP3209321B1 (en) 2014-10-21 2021-06-23 SciClone Pharmaceuticals International Ltd. Treatment of cancer with immune stimulators
BR112017016205A2 (pt) * 2015-02-09 2018-03-27 Romani Luigina thymosin alpha 1 para uso no tratamento de fibrose cística

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) * 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4444757A (en) * 1981-11-16 1984-04-24 Research Corporation Use of thymosin as an anti-diabetes and anti-hypertensive disease agent
TW224053B (no) * 1991-09-13 1994-05-21 Paul B Chretien
US5468729A (en) * 1993-10-26 1995-11-21 Alpha 1 Biomedicals Method for treatment of autoimmune hepatitis
US5760000A (en) * 1994-05-13 1998-06-02 University Technologies International,Inc. Inhibition of liver cancer by the use of GnRH and GnRH analogs
US5888980A (en) * 1994-06-30 1999-03-30 Bio-Logic Research And Development Corporation Compositions for enhancing immune function
US5632983A (en) * 1994-11-17 1997-05-27 University Of South Florida Method for treating secondary immunodeficiency
US5849596A (en) * 1996-07-08 1998-12-15 Food Industry Research And Development Institute Process for determining the smoke content of edible oil
JP2004504585A (ja) * 2000-07-14 2004-02-12 トランスフォーム　ファーマシューティカルズ，インコーポレーティッド． 化合物の組織バリア輸送を最適にするためのシステムおよび方法
EP1343528A2 (en) * 2000-11-02 2003-09-17 Research Foundation of City University of New York Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4

Also Published As

Publication number Publication date
AU2002363248B2 (en) 2007-11-22
MXPA04004187A (es) 2004-07-08
NO327101B1 (no) 2009-04-20
CN1582163A (zh) 2005-02-16
US20050049191A1 (en) 2005-03-03
CA2464307A1 (en) 2003-05-08
EP1450850A1 (en) 2004-09-01
UA80957C2 (en) 2007-11-26
EP1450850B1 (en) 2010-09-22
JP2005511563A (ja) 2005-04-28
EA008536B1 (ru) 2007-06-29
PL208388B1 (pl) 2011-04-29
ES2353379T3 (es) 2011-03-01
NZ532763A (en) 2008-01-31
IL161665A0 (en) 2004-09-27
WO2003037366A1 (en) 2003-05-08
EP1450850A4 (en) 2005-11-30
BR0213823A (pt) 2004-08-31
PL370430A1 (en) 2005-05-30
KR20050042229A (ko) 2005-05-06
US20100221274A1 (en) 2010-09-02
ATE481980T1 (de) 2010-10-15
NO20042100L (no) 2004-05-21
EA200400591A1 (ru) 2004-10-28
DE60237784D1 (de) 2010-11-04
IL161665A (en) 2011-03-31

Similar Documents

Publication Publication Date Title
DK0490991T3 (da) Doseringsform til oral administration af hypoglykæmisk glipizid
IL208184A0 (en) Glp-1, and methods for treating diabetes
EP0637239A4 (en) METHOD FOR PROMOTING NITROGEN RETENTION IN PEOPLE.
KR930702022A (ko) 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법
EA200000468A1 (ru) Терапевтическая композиция для введения толтеродина с контролируемым высвобождением
NO306377B1 (no) Doseform for avgivelse av et medikament
ATE211387T1 (de) Oral 1alpha-hydroxyprevitamin d
WO2001060381B1 (en) Nucleoside analogs with carboxamidine-modified bicyclic base
DE60327843D1 (de) Arzneimittelformulierungen mit verzögerter freisetzung mit einem trägerpeptid
EA200400548A1 (ru) Лечение тяжёлой пневмонии путём введения ингибитора пути тканевого фактора (tfpi)
NO20042100L (no) Fremgangsmate for administrering av et tymosinalfa 1-peptid
DE69615984D1 (de) Verwendung von Ursolsäure zur Herstellung eines Arzneimittels zur Unterdrückung von Metastasen
AR023185A1 (es) Tratamiento de cancer mejorado con temozolomida
RU2008134118A (ru) Внутрижелудочковая доставка белка при боковом амиотрофическом склерозе
ATE342276T1 (de) Nährstoffe aus sojabohnenprotein
JPS60184011A (ja) 免疫調節剤
MY106603A (en) Treatment of genital warts with a combination of liquid nitrogen and recombinant dna human alpha interferon
TW200517119A (en) Method of treatment using interferon-tau
ATE205397T1 (de) Natürliches menschliches alpha interferon enthaltende pharmazeutische zusammensetzungen
SE0200598D0 (sv) Pharmaceutical composition and method for treatment or prevention of vascular disease or states of tissue hypoperfusion with hypoxic and/or ischemic consequences
DE60015306D1 (de) Verwendung von beta interferon zur herstellung eines arzneimittels zur behandlung von ewings sarkom und eoe
MD1780F1 (en) Method of treatment of patients with hepatic cirrhosis
MX9306998A (es) Una composicion terapeutica de tandospirona y forma de dosis paraadministrarla.
ATE332704T1 (de) Behandlung von hepatitis c mit thymosin und pegyliertem interferon
SE8700125L (sv) Korta peptider vid behandling av psoriasis och schizofreni

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees